 This is a single-center, phase III, randomized, prospective, double-blinded, placebo-controlled study of FMT in the treatment of active pediatric CD. The primary aim is to assess safety and feasibility of a weekly FMT maintenance therapy. A total of 60 patients with active CD as defined by PCDAI score of 10 will be enrolled and randomized to receive FMT or placebo-FMT study treatment by retention enema for 1 week and oral, frozen encapsulated inoculaplacebo for 7 weeks. After the first 8 weeks, subjects on FMT who improve or subjects on placebo-FMT who do not improve will have the option to continue on study treatment or switch to open-label FMT until the end of 4 months from study initiation. Subjects will be followed by telephone to assess adverse events for a total of 6 months after their last FMT dose. 